When you think of biotech companies, you may think of exciting young players that haven’t yet commercialized a product. Those exist and, in some cases, make excellent investments. But you also might consider picking up a biotech player that has proven itself and today offers you both innovation and growth.
This type of company is one to hold onto for the long term as it’s already generating revenue but has the research and development strengths to continue building a portfolio of game-changing products. With this in mind, let’s check out one no-brainer biotech stock to buy today and never sell.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
The company I’m talking to has been around for more than 35 years and sells a number of products, from treatments for inflammation to those for cholesterol and eye disease. This player is Regeneron (NASDAQ: REGN), a biotech that’s progressively increased earnings over time, well into the billions of dollars.
Regeneron may be best known for Dupixent, a product it commercializes with partner Sanofi, and one that’s delivered blockbuster revenue. Dupixent is sold for eight inflammation-linked conditions, including common ones such as asthma and atopic dermatitis (also known as eczema). More than one million patients worldwide take this drug.
The company also has relied on Eylea for growth. This is a treatment for wet age-related macular degeneration as well as other diseases of the retina. The lower dose form of Eylea has seen growth slow due to competition — and some of the competition has come from Regeneron’s higher dose version of the treatment, Eylea HD. In the recent quarter, for example, Eylea HD saw U.S. revenue soar 66% to more than $500 million. So this product remains a solid growth driver for Regeneron.
What’s particularly important is that Regeneron has an enormous pipeline with many late-stage programs across therapeutic areas. For example, it currently has more than a dozen candidates involved in phase 3 trials, from immunology and inflammation to cardiovascular, oncology, and rare diseases. And this is just to mention candidates that may be approaching the finish line; Regeneron also has a significant number of candidates in earlier-stage trials.
All of this is positive because, even if only a portion of these candidates reaches commercialization, Regeneron may see growth take off in the coming years. And its deep pipeline ensures that growth will continue over time, with new launches to compensate for declines in older drugs.
Right now, Regeneron is trading for 17x forward earnings estimates, down from more than 25x in the second half of 2024. Considering this biotech’s track record of growth and its solid pipeline, it’s a no-brainer buy at these levels — and a stock you won’t want to let go.
Before you buy stock in Regeneron Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 21, 2026.
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.
1 No-Brainer Biotech Stock To Buy Today and Never Sell was originally published by The Motley Fool
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: finance.yahoo.com
